{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Specimen+PET%2FCT+Scan", "query": { "intervention": "Specimen PET/CT Scan" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 450, "total_pages": 45, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Specimen+PET%2FCT+Scan&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T19:24:04.336Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03375307", "title": "Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Bladder Carcinoma", "Advanced Genitourinary System Carcinoma", "Metastatic Bladder Carcinoma", "Metastatic Genitourinary System Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2020-11-03", "completion_date": "2026-12-16", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-09-10T19:24:04.336Z", "location_count": 17, "location_summary": "Encinitas, California • Irvine, California • La Jolla, California + 12 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03375307" }, { "nct_id": "NCT04595747", "title": "Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Gastrointestinal Stromal Tumor", "Locally Advanced Sarcoma", "Metastatic Gastrointestinal Stromal Tumor", "Metastatic Sarcoma", "Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8", "Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8", "Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8", "Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rogaratinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-05-03", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-10T19:24:04.336Z", "location_count": 18, "location_summary": "Duarte, California • Irvine, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04595747" }, { "nct_id": "NCT07349771", "title": "Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Axatilimab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Skin Biopsy", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2026-06-01", "completion_date": "2033-06-01", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-10T19:24:04.336Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07349771" }, { "nct_id": "NCT07588698", "title": "Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's B-cell Lymphoma", "Lymphoma Non-Hodgkin", "Diffuse Large B-Cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP)", "type": "DRUG" }, { "name": "Epcoritamab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Positron Emission Tomography (PET)", "type": "PROCEDURE" }, { "name": "Blood specimen collection", "type": "PROCEDURE" }, { "name": "Questionnaires", "type": "BEHAVIORAL" }, { "name": "Computerized tomography (CT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "Carrie Ho, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-09-15", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-10T19:24:04.336Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07588698" }, { "nct_id": "NCT07195734", "title": "Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Locally Recurrent Head and Neck Squamous Cell Carcinoma", "Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Locally Recurrent Laryngeal Squamous Cell Carcinoma", "Locally Recurrent Oral Cavity Squamous Cell Carcinoma", "Locally Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage II Laryngeal Cancer AJCC v8", "Stage II Lip and Oral Cavity Cancer AJCC v8", "Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Salvage Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2026-04-24", "completion_date": "2033-02-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-10T19:24:04.336Z", "location_count": 110, "location_summary": "Tucson, Arizona • Los Angeles, California • Palo Alto, California + 80 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07195734" }, { "nct_id": "NCT05836584", "title": "Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage I Gastric Cancer AJCC v8", "Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage II Gastric Cancer AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Lymphadenectomy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2023-12-06", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-09-10T19:24:04.336Z", "location_count": 133, "location_summary": "Dublin, California • Fremont, California • Fresno, California + 99 more", "locations": [ { "city": "Dublin", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Modesto", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05836584" }, { "nct_id": "NCT05755087", "title": "Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Tegavivint", "type": "DRUG" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Lapo Alinari", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2023-03-06", "completion_date": "2028-03-05", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-10T19:24:04.336Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05755087" }, { "nct_id": "NCT05781321", "title": "Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Accelerated Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorodopa F 18", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2023-03-23", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-10T19:24:04.336Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Albert Lea", "state": "Minnesota" }, { "city": "Mankato", "state": "Minnesota" }, { "city": "Northfield", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05781321" }, { "nct_id": "NCT06483048", "title": "MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Fallopian Tube Carcinosarcoma", "Recurrent Female Reproductive System Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Carcinosarcoma", "Recurrent Platinum-Resistant Fallopian Tube Carcinoma", "Recurrent Platinum-Resistant Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Carcinosarcoma", "Refractory Fallopian Tube Carcinoma", "Refractory Female Reproductive System Carcinoma", "Refractory Ovarian Carcinoma", "Refractory Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Autologous MUC1-activated T-cells", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 12, "start_date": "2024-09-20", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-09-10T19:24:04.336Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06483048" }, { "nct_id": "NCT07061964", "title": "Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Muscle Invasive Bladder Urothelial Carcinoma", "Stage II Bladder Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cystoscopy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Photon Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Transurethral Resection of Bladder Tumor", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2025-11-25", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-10T19:24:04.336Z", "location_count": 165, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 130 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07061964" } ] }